Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apraglutide in Short Bowel Syndrome with Intestinal Failure
NCT04627025Phase 3Completed
- Sponsor
- VectivBio
- Start
- Jan 2021
- Primary completion
- Jan 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in short bowel syndrome (SBS) comparing Apraglutide with Placebo (2 arms). Primary endpoint: Relative change from baseline in actual weekly PS volume at Week 24. Started Jan 2021; status: completed.
02
Drugs
apraglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT04627025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04627025.